Details of Drug

Drug General Information (ID: D1156)
Drug Name	Norgestimate
Drug Type	Small molecule
Drug Synonymous	Norgestimato; Norgestimatum; Dexnorgestrel acetime; Norgestrel oxime acetate; D 138; ORF 10131; RWJ 10131; Norgestimato [INN-Spanish]; Norgestimatum [INN-Latin]; ORF-10131; Ortho-Prefest; RWJ-10131; Norgestimate (USP/INN); Norgestimate [USAN:INN:BAN]; D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-oneoxime; D-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime; [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate; (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester); (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate Click to Show/Hide
Disease Class	QA21: Contraceptive management
Therapeutic Class	Contraceptive Agents
Structure
Structure	3D Structure		2D Structure
Formula	C23H31NO3
InChI	1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1
InChIKey	KIQQMECNKUGGKA-NMYWJIRASA-N
Canonical SMILES	CCC12CCC3C(C1CCC2(C#C)OC(=O)C)CCC4=CC(=NO)CCC34
External Link
	Pubchem ID	6540478
	CAS Number	20799-27-3
	CHEBI ID	50815
	TTD ID	D09QZI
	INTEDE ID	DR1178

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM007 Pharmacodynamic antagonistic effects BM003 Complex formation BM009 Altered absorption (Unspecific) BM016 Altered formation of CYP450 enzymes BM017 CYP450 enzyme inhibition BM019 UGT inhibition BM020 Decreased metabolism due to hepatotoxicity BM022 CYP450 enzyme induction BM025 Decreased metabolism (Unspecific) BM032 Decreased renal excretion (Unspecific) BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Norgestimate
Affected gastrointestinal absorption
	Complex formation					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0381		Colesevelam	C31H67Cl3N4O	160051	Moderate		Inter Info	[21], [13], [42]
	Altered absorption (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1068		Miltefosine	C21H46NO4P	3599	Moderate		Inter Info	[21], [13], [52]
Affected intra/extra-hepatic metabolism
	Altered formation of CYP450 enzymes					Drug Num: 18
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0023		Adalimumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D0032		Alefacept	NA	NA	Moderate		Inter Info	[36], [37], [38]
D0085		Anakinra	C20H23N5O7S2	146171046	Moderate		Inter Info	[36], [37], [38]
D0614		Etanercept	NA	NA	Moderate		Inter Info	[36], [37], [38]
D0802		Infliximab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D0246		Canakinumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D0304		Certolizumab pegol	NA	NA	Moderate		Inter Info	[36], [37], [38]
D0564		Emapalumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D0736		Golimumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D0747		Guselkumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D0875		Ixekizumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D1403		Rilonacept	NA	NA	Moderate		Inter Info	[36], [37], [38]
D1447		Sarilumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D1448		Satralizumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D1454		Secukinumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D1467		Siltuximab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D1599		Tocilizumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
D1671		Ustekinumab	NA	NA	Moderate		Inter Info	[36], [37], [38]
	CYP450 enzyme inhibition					Drug Num: 8
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0692		Fosamprenavir	C25H36N3O9PS	131536	Major		Inter Info	[21], [13], [22]
D1596		Tizanidine	C9H8ClN5S	5487	Major		Inter Info	[33], [34], [35]
D0116		Atazanavir	C38H52N6O7	148192	Moderate		Inter Info	[21], [13], [45]
D0426		Darunavir	C27H37N3O7S	213039	Moderate		Inter Info	[46], [31]
D0906		Letermovir	C29H28F4N4O4	45138674	Moderate		Inter Info	[39], [30], [49]
D0944		Lomitapide	C39H37F6N3O2	9853053	Moderate		Inter Info	[13], [50]
D1050		Metreleptin	NA	NA	Moderate		Inter Info	[21], [13], [51]
D1455		Selegiline	C13H17N	26757	Moderate		Inter Info	[57], [58], [59]
	Decreased metabolism due to hepatotoxicity					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0114		Asparaginase Escherichia coli	NA	NA	Moderate		Inter Info	[39], [30], [40]
D0113		Asparaginase Erwinia chrysanthemi	NA	NA	Moderate		Inter Info	[39], [30], [40]
D0232		Calaspargase pegol	NA	NA	Moderate		Inter Info	[39], [30], [40]
D1234		Pegaspargase	C14H19NO	436058	Moderate		Inter Info	[39], [30], [40]
	CYP450 enzyme induction					Drug Num: 31
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0080		Amprenavir	C25H35N3O6S	65016	Major		Inter Info	[1], [2], [3]
D0178		Bexarotene	C24H28O2	82146	Major		Inter Info	[4], [5], [6]
D0194		Bosentan	C27H29N5O6S	104865	Major		Inter Info	[4], [7], [6]
D0255		Carbamazepine	C15H12N2O	2554	Major		Inter Info	[8], [9], [10]
D0639		Felbamate	C11H14N2O4	3331	Major		Inter Info	[8], [9], [10]
D0741		Griseofulvin	C17H17ClO6	441140	Major		Inter Info	[11], [1], [12]
D0192		Boceprevir	C27H45N5O5	10324367	Major		Inter Info	[4], [16], [17]
D0204		Brigatinib	C29H39ClN7O2P	68165256	Major		Inter Info	[13], [18]
D0406		Dabrafenib	C23H20F3N5O2S2	44462760	Major		Inter Info	[4], [19], [6]
D0569		Encorafenib	C22H27ClFN7O4S	50922675	Major		Inter Info	[13], [20]
D0601		Eslicarbazepine	C15H14N2O2	9881504	Major		Inter Info	[8], [9], [10]
D0697		Fosphenytoin	C16H15N2O6P	56339	Major		Inter Info	[8], [9], [10]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Major		Inter Info	[23], [6], [12]
D1265		Phenobarbital	C12H12N2O3	4763	Major		Inter Info	[8], [9], [10]
D1400		Rifampicin	C43H58N4O12	135398735	Major		Inter Info	[24], [25], [26]
D1401		Rifapentine	C47H64N4O12	135403821	Major		Inter Info	[24], [25], [26]
D1502		St. John's Wort	NA	NA	Major		Inter Info	[27], [28], [29]
D1541		Telaprevir	C36H53N7O6	3010818	Major		Inter Info	[4], [16], [17]
D1198		Oxcarbazepine	C15H12N2O2	34312	Major		Inter Info	[8], [9], [10]
D1283		Phenytoin	C15H12N2O2	1775	Major		Inter Info	[8], [9], [10]
D1340		Primidone	C12H14N2O2	4909	Major		Inter Info	[8], [9], [10]
D1399		Rifabutin	C46H62N4O11	135398743	Major		Inter Info	[24], [25], [26]
D0356		Clobazam	C16H13ClN2O2	2789	Moderate		Inter Info	[4], [13], [41]
D1081		Modafinil	C15H15NO2S	4236	Moderate		Inter Info	[4], [43], [44]
D0106		Armodafinil	C15H15NO2S	9690109	Moderate		Inter Info	[4], [43], [44]
D0568		Enasidenib	C19H17F6N7O	89683805	Moderate		Inter Info	[21], [13], [47]
D0905		Lesinurad	C17H14BrN3O2S	53465279	Moderate		Inter Info	[21], [13], [48]
D1167		Olaparib	C24H23FN4O3	23725625	Moderate		Inter Info	[30], [4], [54]
D1253		Perampanel	C23H15N3O	9924495	Moderate		Inter Info	[30], [4], [55]
D1302		Pitolisant	C17H26ClNO	9948102	Moderate		Inter Info	[30], [4], [56]
D0208		Brivaracetam	C11H20N2O2	9837243	Minor		Inter Info	[63], [64], [65]
	Decreased metabolism (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0617		Ethanol	C2H6O	702	Minor		Inter Info	[21], [13], [61]
Affected excretion pathways
	Decreased renal excretion (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1110		Naratriptan	C17H25N3O2S	4440	Minor		Inter Info	[21], [13], [62]
Pharmacodynamic antagonistic effects
	Attenuated pharmacological effects (Unspecific)					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1094		Mycophenolate mofetil	C23H31NO7	5281078	Major		Inter Info	[13], [14], [15]
D1095		Mycophenolic acid	C17H20O6	446541	Major		Inter Info	[13], [14], [15]
D1894		Sugammadex	C72H112O48S8	6918585	Major		Inter Info	[30], [31], [32]
D1124		Neratinib	C30H29ClN6O3	9915743	Moderate		Inter Info	[53], [39]
D1664		Ulipristal	C28H35NO3	13559281	Moderate		Inter Info	[30], [60], [31]

References
1	FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 31 (2005): 139-51. [PMID: 15921558]
2	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
3	Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids 14 (2000): 1333-9.[PMID: 10930147]
4	Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
5	Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.
6	Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997): 2453-8. [PMID: 9385296]
7	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
8	Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
9	Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E "Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women." Epilepsia 40 (1999): 783-7. [PMID: 10368079]
10	Odlind V, Olsson SE "Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with norplant implants." Contraception 33 (1986): 257-61. [PMID: 3087695]
11	Cote J "Interaction of griseofulvin and oral contraceptives." J Am Acad Dermatol 22 (1990): 124-5. [PMID: 2298948]
12	van Dijke CP, Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J (Clin Res Ed) 288 (1984): 1125-6. [PMID: 2143563]
13	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
14	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
15	Product Information. Myfortic (mycophenolic acid). Novartis Pharmaceuticals, East Hanover, NJ.
16	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
17	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
18	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
19	Product Information. Tafinlar (dabrafenib). GlaxoSmithKline, Research Triangle Park, NC.
20	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
21	Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
22	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
23	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
24	Back DJ, Breckenridge AM, Crawford F, et al. "The effect of rifampicin on norethisterone pharmacokinetics." Eur J Clin Pharmacol 15 (1979): 193-7. [PMID: 37091]
25	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
26	Venkatesan K "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet 22 (1992): 47-65. [PMID: 1559307]
27	Ernst E "Second thoughts about safety of St John's wort." Lancet 354 (1999): 2014-6. [PMID: 10636361]
28	Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8. [PMID: 10675182]
29	Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH "St John's Wort: Effect on CYP3A4 activity." Clin Pharmacol Ther 67 (2000): 451-7. [PMID: 10824623]
30	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31	Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24. [PMID: 8751044]
32	Product Information. Bridion (sugammadex). Merck &amp Company Inc, Whitehouse Station, NJ.
33	Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2." Clin Pharmacol Ther 78 (2005): 400-11. [PMID: 16198659]
34	Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ "Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism." Clin Pharmacol Ther 76 (2004): 598-606. [PMID: 15592331]
35	Product Information. Vioxx (rofecoxib). Merck &amp Co, Inc, West Point, PA.
36	Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
37	Product Information. Ilaris (canakinumab). Novartis Pharmaceuticals, East Hanover, NJ.
38	Product Information. Skyrizi (risankizumab). AbbVie US LLC, North Chicago, IL.
39	Cerner Multum, Inc. "Australian Product Information.".
40	Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.
41	Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
42	Product Information. Welchol (colesevelam) Daiichi Sankyo, Inc., Parsippany, NJ.
43	Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
44	Product Information. Provigil (modafinil). Cephalon, Inc, West Chester, PA.
45	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
46	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
47	Product Information. Idhifa (enasidenib). Celgene Corporation, Summit, NJ.
48	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
49	Product Information. Prevymis (letermovir). Merck &amp Company Inc, Whitehouse Station, NJ.
50	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
51	Product Information. Myalept (metreleptin). Bristol-Myers Squibb, Princeton, NJ.
52	Product Information. Impavido (miltefosine). Paladin Therapeutics Inc, Wilmington, DE.
53	Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
54	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
55	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
56	Product Information. Wakix (pitolisant). Harmony Biosciences, LLC, Plymouth Meeting, PA.
57	Ito D, Amano T, Sato H, Fukuuchi Y "Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease." J Neurol 248 (2001): 533-4. [PMID: 11499649]
58	Laine K, Anttila M, Helminen A, Karnani H, Huupponen R "Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids." Br J Clin Pharmacol 47 (1999): 249-54. [PMID: 10215747]
59	McGrath PJ, Stewart JW, Quitkin FM "A possible L-deprenyl induced hypertensive reaction." J Clin Psychopharmacol 9 (1989): 310-1. [PMID: 2504782]
60	Product Information. ella (ulipristal). Afaxys Inc., Charleston, SC.
61	Hobbes J, Boutagy J, Shenfield GM "Interactions between ethanol and oral contraceptive steroids." Clin Pharmacol Ther 38 (1985): 371-80. [PMID: 4042520]
62	Product Information. Amerge (naratriptan). Glaxo Wellcome, Research Triangle Park, NC.
63	Product Information. Briviact (brivaracetam). UCB Pharma Inc, Smyrna, GA.
64	Stockis A, Rolan P "Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women." J Clin Pharmacol 53 (2013): 1313-21. [PMID: 24386664]
65	Stockis A, Watanabe S, Fauchoux N "Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study." Epilepsia 55 (2014): e27-31. [PMID: 24512385]

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence